NVS
Price
$117.95
Change
-$0.88 (-0.74%)
Updated
Jun 25, 01:12 PM (EDT)
Capitalization
197.93B
22 days until earnings call
PFE
Price
$24.30
Change
-$0.01 (-0.04%)
Updated
Jun 25, 01:14 PM (EDT)
Capitalization
157.14B
41 days until earnings call
Interact to see
Advertisement

NVS vs PFE

Header iconNVS vs PFE Comparison
Open Charts NVS vs PFEBanner chart's image
Novartis AG
Price$117.95
Change-$0.88 (-0.74%)
Volume$1.8K
Capitalization197.93B
Pfizer
Price$24.30
Change-$0.01 (-0.04%)
Volume$64.95K
Capitalization157.14B
NVS vs PFE Comparison Chart in %
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. PFE commentary
Jun 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 25, 2025
Stock price -- (NVS: $118.83 vs. PFE: $24.31)
Brand notoriety: NVS: Not notable vs. PFE: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 66% vs. PFE: 80%
Market capitalization -- NVS: $197.93B vs. PFE: $157.14B
NVS [@Pharmaceuticals: Major] is valued at $197.93B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, NVS is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).

  • NVS’s TA Score: 5 bullish, 4 bearish.
  • PFE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NVS is a better buy in the short-term than PFE.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +2.08% price change this week, while PFE (@Pharmaceuticals: Major) price change was +1.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.41%. For the same industry, the average monthly price growth was +4.57%, and the average quarterly price growth was +8.03%.

Reported Earning Dates

NVS is expected to report earnings on Jul 17, 2025.

PFE is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.41% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($198B) has a higher market cap than PFE($157B). PFE has higher P/E ratio than NVS: PFE (74.92) vs NVS (23.38). NVS YTD gains are higher at: 26.511 vs. PFE (-5.076). NVS has higher annual earnings (EBITDA): 18.3B vs. PFE (9.56B). NVS has more cash in the bank: 14B vs. PFE (12.7B). NVS has less debt than PFE: NVS (26.3B) vs PFE (70.8B). PFE has higher revenues than NVS: PFE (58.5B) vs NVS (46.7B).
NVSPFENVS / PFE
Capitalization198B157B126%
EBITDA18.3B9.56B191%
Gain YTD26.511-5.076-522%
P/E Ratio23.3874.9231%
Revenue46.7B58.5B80%
Total Cash14B12.7B110%
Total Debt26.3B70.8B37%
FUNDAMENTALS RATINGS
NVS vs PFE: Fundamental Ratings
NVS
PFE
OUTLOOK RATING
1..100
7379
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
15100
SMR RATING
1..100
2974
PRICE GROWTH RATING
1..100
4758
P/E GROWTH RATING
1..100
7996
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as NVS (16). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that NVS’s stock grew significantly faster than PFE’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (74). This means that NVS’s stock grew somewhat faster than PFE’s over the last 12 months.

NVS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as PFE (58). This means that NVS’s stock grew similarly to PFE’s over the last 12 months.

NVS's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that NVS’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSPFE
RSI
ODDS (%)
Bearish Trend 3 days ago
47%
Bearish Trend 3 days ago
55%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
43%
Bearish Trend 3 days ago
56%
Momentum
ODDS (%)
Bearish Trend 3 days ago
48%
Bullish Trend 3 days ago
45%
MACD
ODDS (%)
Bearish Trend 3 days ago
40%
Bearish Trend 3 days ago
63%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
44%
Bearish Trend 3 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
45%
Bullish Trend 3 days ago
50%
Advances
ODDS (%)
Bullish Trend 20 days ago
47%
Bullish Trend 3 days ago
56%
Declines
ODDS (%)
Bearish Trend 6 days ago
45%
Bearish Trend 8 days ago
60%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
56%
Aroon
ODDS (%)
Bullish Trend 3 days ago
40%
Bullish Trend 3 days ago
51%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MOGO1.250.07
+5.93%
Mogo
VVX47.001.26
+2.75%
V2X
NUKK11.150.11
+1.00%
Nukkleus Inc New
SHW345.691.92
+0.56%
Sherwin-Williams Company (The)
BLCO12.040.04
+0.33%
Bausch + Lomb Corp

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.11%
GSK - NVS
65%
Loosely correlated
+1.10%
AZN - NVS
62%
Loosely correlated
-0.14%
JNJ - NVS
55%
Loosely correlated
+0.57%
PFE - NVS
54%
Loosely correlated
+1.17%
AMGN - NVS
51%
Loosely correlated
+1.85%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
+1.17%
GSK - PFE
60%
Loosely correlated
+1.10%
AMGN - PFE
58%
Loosely correlated
+1.85%
ABBV - PFE
55%
Loosely correlated
+0.97%
NVS - PFE
54%
Loosely correlated
+1.11%
BMY - PFE
51%
Loosely correlated
+0.23%
More